Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

UBS cuts RELX to ‘sell’, believes earnings acceleration which drove material outperformance over last 3 years “coming to an end”

Following a 17% share price appreciation in the last three months, in part driven by a weaker pound, the Swiss bank has left its target price for RELX unchanged at 1,555p
Publishing
That is below the FTSE 100-listed publisher's current share price of 1,600p, down 3.3% on Wednesday’s close

UBS has put a dampener on shares in RELX PLC (LON:REL), downgrading its rating for the Anglo-Dutch publishing group to ‘sell’ from ‘neutral’ as they believe “an earnings acceleration which drove material outperformance over the last 3yrs is coming to an end”.

Following a 17% share price appreciation in the last three months, in part driven by a weaker pound, the Swiss bank has left its target price for the FTSE 100-listed firm unchanged at 1,555p, which is below the current share price of 1,600p, down 3.3% on Wednesday’s close.

READ: RELX issues "steady as she goes" AGM statement

In a note to clients, UBS’s analysts noted three reasons for their downgrade: “1) we forecast underlying earnings growth to decelerate from +6% in 2017 to +5% in FY18-21, 2) we see increasing structural risk to RELX's Journal business (c20% of group revs, 55% of STM); and 3) we believe RELX's valuation is full on 19x FY19E EPS with risks now firmly skewed to the downside. “

They added: “Our upside/downside spectrum shows only 6% upside with 28% downside. Further, marking RELX's divisions to listed peers suggests the stock is 7% overvalued at current prices.”

View full REL profile View Profile

RELX PLC Timeline

Related Articles

Email
August 15 2018
Milan Patel, dotdigital’s chief executive officer said: "This year reflects substantial progress against the company's strategic aims in accelerating our platform capabilities into the omnichannel space, continuing to innovate our product, growing geographically and deepening our relationships with our strategic partners”
ipad
September 19 2018
“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients”
Apollo 11
February 22 2018
Immersive VR, a technology company focused on the education space, was the first company Sure backed

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use